A ranar 13 ga Janairu, 2022, Green Valley (Shanghai) Pharmaceuticals Co., Ltd. ta karɓi wasiƙar daga Hukumar Abinci da Magunguna ta Amurka (FDA) kan aikace-aikacen Sabbin Magunguna na Bincike (IND) don gwajin gwaji na asibiti na duniya da yawa-II na Oligomannate (wanda aka sayar da shi azaman "GV-971"), sabon magungunan kamfanin don magance cutar Alzheimer (AD). Wasiƙar ta nuna "Nazari na iya Ci gaba" tare da bincike na asibiti da aka ba da shawara a cikin kula da marasa lafiya masu ciwon Parkinson na farko (PD). Kwanan aikin IND shine Disamba 16, 2021.
ABUBUWAN DA ZA KU GUDU DAGA WANNAN LABARI:
- received the letter from the US Food and Drug Administration (FDA) on the Investigational New Drug (IND) application for the global multi-center phase-II clinical trial of Oligomannate (marketed as “GV-971”), the company’s innovative drug for treating Alzheimer’s disease (AD).
- The IND effective date is December 16, 2021.
- The letter indicated the “Study May Proceed”.
